MedWatch

Top news from MedWatch this week

Miss anything?

Photo: MedWatch

Monday

Production limitations put a damper on Novo Nordisk’s potential growth

Eargo enters million-dollar settlement with the United States

Lundbeck veteran reflects as he nears 25-year anniversary: ”Don’t forget your roots”

Novo Nordisk remains coy over Wegovy blockbuster potential

Tuesday

Eli Lilly wants to gain on Novo Nordisk’s obesity lead

Demant predicts USD 14m impact of war in Ukraine in first ever quarterly report

Investors asked Demant for more transparency – now they have it

Novo Nordisk confirms start of phase I robotic pill trial

Leo Pharma takes hand eczema treatment into phase III

Wednesday

Ambu obtains CE mark for fifth generation single-use bronchoscope

Bose to drop hearing aid business, media reports

Analyst: Bose hearing aid exit reflects market complexity

EU proposes cross-border data space to strengthen health union

Thursday

GN Hearing beats analyst expectations for Q1

GN Hearing lets staff go to optimize supply chain

GN Hearing CEO: Bose’s exit spotlights complexity of hearing aid market

WS Audiology’s revenue grew by 20% in Q2 2021/2022

WSA maintains guidance despite strong growth – CEO explains why

Coloplast downgrades organic growth guidance

Ambu downgrades financial guidance

Friday

GN Hearing in talks with VA on new hybrid product category

Coloplast’s biggest ever acquisition lands firm USD 40m in two months

Potential buyers prepared to chase arimoclomol approval, Orphazyme deputy chair says

Coloplast will not exit Russia, says CEO

Ambu to reign in expectations after seventh downgrade since 2019


More from MedWatch

Further reading

Latest news

See all jobs